The Risk of Relapse in Papillary Thyroid Cancer (PTC) in the Context of BRAFV600E Mutation Status and Other Prognostic Factors.

INTRODUCTION:The risk of over-treatment in low-advanced PTC stages has prompted clinicians to search for new reliable prognostic factors. The presence of BRAF mutation, the most frequent molecular event in PTC, seems to be a good candidate. However, there is still lack of randomised trials and its s...

Full description

Bibliographic Details
Main Authors:	Agnieszka Czarniecka, Monika Kowal, Dagmara Rusinek, Jolanta Krajewska, Michal Jarzab, Ewa Stobiecka, Ewa Chmielik, Ewa Zembala-Nozynska, Stanislaw Poltorak, Aleksander Sacher, Adam Maciejewski, Jadwiga Zebracka-Gala, Dariusz Lange, Malgorzata Oczko-Wojciechowska, Daria Handkiewicz-Junak, Barbara Jarzab
Format:	Article
Language:	English
Published:	Public Library of Science (PLoS) 2015-01-01
Series:	PLoS ONE
Online Access:	http://europepmc.org/articles/PMC4503446?pdf=render

Internet

http://europepmc.org/articles/PMC4503446?pdf=render

The Risk of Relapse in Papillary Thyroid Cancer (PTC) in the Context of BRAFV600E Mutation Status and Other Prognostic Factors.

Internet

Similar Items